HerzSupplement - Pentalong von Actavis

Herz Supplement
Cardiovascular Diseases
4. Thum T. Bauersachs J. Microarray-based gene
expression profiling to elucidate cellular responses
to nitric oxide – a review from an analytical
and biomedical point of view. J Chromatogr
B Analyt Technol Biomed Life Sc 2007;
851(1–2):3–11
5. Pilz R.B. Casteel D.E. Regulation of gene expression
by cyclic GMP. Circ Res 2003;93(11):1034–
1046
6. Dhakshinamoorthy S et al. Protein/DNA arrays
identify nitric oxide-regulated cis-element and
trans-factor activities some of which govern
neuroblastoma cell viability. Nucleic Acids Res
2007;35(16):5439–5451
7. Akool el S et al. Nitric oxide increases the decay
of matrix metalloproteinase 9 mRNA by inhibiting
the expression of mRNA-stabilizing factor
HuR. Mol Cell Biol 2003;23(14):4901–4916
8. Kuwano Y et al. Analysis of nitric oxide-stabilized
mRNAs in human fibroblasts reveals HuRdependent
heme oxygenase 1 upregulation.
Mol Cell Biol 2009;29(10):2622–2635
9. Hentze MW, Kuhn LC. Molecular control of vertebrate
iron metabolism: mRNA-based regulatory
circuits operated by iron, nitric oxide, and
oxidative stress. Proc Natl Acad Sci U S A 1996;
93(16):8175–8182
10. Zhou J et al. NO and TNF-alpha released from
activated macrophages stabilize HIF-1alpha in
resting tubular LLC-PK1 cells. Am J Physiol Cell
Physiol 2003;284(2):C439–446
11. Wang EQ et al. cDNA microarray analysis of vascular
gene expression after nitric oxide donor
infusions in rats: implications for nitrate tolerance
mechanisms. AAPS PharmSci 2002; 4(2):
E10
12. Stalleicken D, Schröder H. In-vivo- und Humanstudien
bestätigen das antioxidative und toleranzfreie
Wirkprofil von PETN. Perfusion 2008;
21:4–6
13. Dhakshinamoorthy S, Porter AG. Nitric oxideinduced
transcriptional up-regulation of protective
genes by Nrf2 via the antioxidant response
element counteracts apoptosis of neuroblastoma
cells. J Biol Chem 2004;279(19):
20096–20107
14. Misquitta CM et al. The role of 3‘-untranslated
region (3‘-UTR) mediated mRNA stability in cardiovascular
pathophysiology. Mol Cell Biochem
2001;224(1–2):53–67
15. Khabar KS. The AU-rich transcriptome: more than
interferons and cytokines, and its role in disease.
J Interferon Cytokine Res 2005;25(1):1–10.
16. Pautz A et al. Effects of nitroglycerin or pentaerithrityl
tetranitrate treatment on the gene
expression in rat hearts: evidence for cardiotoxic
and cardioprotective effects. Physiol Genomics
2009;38(2):176–185
17. Clarke PA et al. Gene expression microarray analysis
in cancer biology, pharmacology, and drug
development: progress and potential. Biochem
Pharmacol 2001;62(10):1311–1336
18. Gupta S et al. Activation of nuclear factor-kappaB
is necessary for myotrophin-induced cardiac
hypertrophy. J Cell Biol 2002;159(6):1019–
1028
19. Wang J et al. Convergence of protein kinase
C and JAK-STAT signaling on transcription factor
GATA-4. Mol Cell Biol 2005;25(22):9829–
9844.
20. Thuerauf DJ et al. p38 Mitogen-activated protein
kinase mediates the transcriptional induction
of the atrial natriuretic factor gene through
a serum response element. A potential role for
the transcription factor ATF6. J Biol Chem 1998;
273(32):20636–20643
21. Xu J et al. Myocyte enhancer factors 2A and 2C
induce dilated cardiomyopathy in transgenic
mice. J Biol Chem 2006;281(14): 9152–9162
22. Aerts S et al. TOUCAN 2: the all-inclusive open
source workbench for regulatory sequence analysis.
Nucleic Acids Res 2005;33(Web Server issue):W393–396
23. Chekmenev DS et al. P-Match: transcription factor
binding site search by combining patterns
and weight matrices. Nucleic Acids Res 2005;
33(Web Server issue):W432–437
24. Nunez C et al. Discrepancies between nitroglycerin
and NO-releasing drugs on mitochondrial
oxygen consumption, vasoactivity,
and the release of NO. Circ Res 2005; 97(10):
1063–1069
25. Kleschyov AL et al. Does nitric oxide mediate the
vasodilator activity of nitroglycerin? Circ Res
2003;93(9):e104–112
26. Munzel T et al. Explaining the phenomenon
of nitrate tolerance. Circ Res 2005;97(7):618–
628
27. Daiber A et al. Oxidative stress and mitochondrial
aldehyde dehydrogenase activity: a comparison
of pentaerythritol tetranitrate with other
organic nitrates. Mol Pharmacol 2004; 66(6):
1372–1382
28. Janero DR et al. Differential nitros(yl)ation of
blood and tissue constituents during glyceryl
trinitrate biotransformation in vivo. Proc Natl
Acad Sci U S A 2004;101(48):16958–16963
29. Wenzel P et al. Number of nitrate groups determines
reactivity and potency of organic nitrates:
a proof of concept study in ALDH-2-/-
mice. Br J Pharmacol 2007;150(4):526–533
30. Gori T, Daiber A. Non-hemodynamic effects of
organic nitrates and the distinctive characteristics
of pentaerithrityl tetranitrate. Am J Cardiovasc
Drugs, 2009;9(1):7–15
31. Tassorelli C, Joseph SA. NADPH-diaphorase activity
and Fos expression in brain nuclei following
nitroglycerin administration. Brain Res 1995;
695(1):37–44
32. Tassorelli C et al. A role for brain cyclooxygenase-2
and prostaglandin-E2 in migraine: effects
of nitroglycerin. Int Rev Neurobiol 2007;82:373–
382
33. Greco R et al. Neuroprotective effect of nitroglycerin
in a rodent model of ischemic stroke:
evaluation of Bcl-2 expression. Int Rev Neurobiol
2007;82:423–435
34. Munzel T et al. Effects of long-term nitroglycerin
treatment on endothelial nitric oxide synthase
(NOS III) gene expression, NOS III-mediated superoxide
production, and vascular NO bioavailability.
Circ Res 2000;86(1):E7–E12
35. Prevotat L et al. Nitric oxide-induced down-regulation
of beta-catenin in colon cancer cells by
a proteasome-independent specific pathway.
Gastroenterology 2006;131(4):1142–1152
36. Suwattanasophon C et al. 5-HT(1B/1D) serotonin
receptor agonist attenuates nitroglycerin-evoked
nitric oxide synthase expression in trigeminal
pathway. Cephalalgia 2003;23(8):825–832
37. Yamazaki A, Birnboim H.C. Potentiation of retinoic
acid-induced U-937 differentiation into
respiratory burst-competent cells by nitric oxide
donors. Leuk Res 1995;19(5):325–335
38. Otto A et al. Rosuvastatin treatment protects
against nitrate-induced oxidative stress in
eNOS knockout mice: implication of the
NAD(P)H oxidase pathway. Br J Pharmacol 2006;
148(4):544–552.
39. Li J et al. Nitroglycerin protects small intestine
from ischemia-reperfusion injury via NO-cGMP
pathway and upregulation of alpha-CGRP. J
Gastrointest Surg 2009;13(3):478–485
40. Death AK et al. Nitroglycerin upregulates matrix
metalloproteinase expression by human
macrophages. J Am Coll Cardiol 2002;39(12):
1943–1950.
41. Szocs K et al. Increased superoxide production
in nitrate tolerance is associated with NAD(P)H
oxidase and aldehyde dehydrogenase 2 downregulation.
J Mol Cell Cardiol 2007;42(6):1111–
1118
42. Pi X et al. Differential expression of genes from
nitrate-tolerant rat aorta. J Vasc Res 2002; 39(4):
304–310
43. Oberle S et al. The antioxidant defense protein
ferritin is a novel and specific target for pentaerithrityl
tetranitrate in endothelial cells. Biochem
Biophys Res Commun 1999;261(1):28–34
44. Oberle S et al. Heme oxygenase-1 induction may
explain the antioxidant profile of pentaerythrityl
trinitrate. Biochem Biophys Res Commun
2002;290(5):1539–1544
45. Mollnau H et al. Mitochondrial oxidative stress
and nitrate tolerance – comparison of nitroglycerin
and pentaerithrityl tetranitrate in
Mn-SOD+/- mice. BMC Cardiovasc Disord 2006;
6:44.
46. Dragoni S et al. Pentaerythrityl tetranitrate and
nitroglycerin, but not isosorbide mononitrate,
prevent endothelial dysfunction induced by ischemia
and reperfusion. Arterioscler Thromb
Vasc Biol 2007;27(9):1955–1959
Für die Verfasser:
Prof. Dr. Hartmut Kleinert
Institut für Pharmakologie, Universitätsmedizin
der Johannes Gutenberg-
Universität, Obere Zahlbacher Str. 63
55101 Mainz, Germany
Tel.: +49 (0) 6131 17 9276
Fax: +49 (0) 6131 17 9042
66 Herz 35 · 2010 · Supplement II © Urban & Vogel